SCHEDULE: TCG Crossover Discloses 7.9% Stake in Fulcrum Therapeutics

TCG Crossover Fund II, L.P. and associated entities have reported a 7.9% beneficial ownership stake in Fulcrum Therapeutics, Inc.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu filed an amendment to their Schedule 13G regarding their investment in Fulcrum Therapeutics, Inc.
• The reporting persons collectively hold 5,250,000 shares of common stock.
• This holding represents 7.9% of the total outstanding common stock of the issuer, based on 66,633,321 shares outstanding as of April 20, 2026.
• The reporting persons maintain shared voting and dispositive power over the shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing confirming existing institutional support without indicating new strategic shifts or material changes in company operations.

Positives

• Institutional investor maintains a significant 7.9% equity position, signaling long-term interest in the company.

Negatives

• None identified in this ownership disclosure.

Risks

• The reporting persons certify that the shares are not held for the purpose of changing or influencing the control of the issuer, which limits their role to passive investment.

Future Outlook

The filing does not provide forward-looking guidance on the company's operations, as it is a regulatory disclosure of ownership.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory update for institutional investors in the biotechnology sector, reflecting ongoing portfolio management by specialized life sciences venture firms.

Comparison to Industry Standards

• The filing follows standard SEC requirements for institutional investors holding more than 5% of a public company's equity.
• The passive investment stance is consistent with typical venture capital exit or holding strategies in the biotech space.

Stakeholder Impact

• Shareholders may view the continued 7.9% stake as a sign of stability and institutional confidence in the issuer.

Next Steps

• Continued monitoring of future 13G or 13D filings by the reporting persons for any changes in their investment position.

Key Dates

Keywords

Fulcrum Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Biotech Investment